ICADE SANTE (EPA:ICSAA) CONSULTATION OF THE NOTEHOLDERS IN THE CONTEXT OF THE CONTEMPLATED INITIAL PUBLIC OFFERING OF ICADE SANTÉ

Transparency directive : regulatory news

09/07/2021 08:45

PRESS RELEASE
Paris, July 09, 2021, 08:45 a.m.

CONSULTATION OF THE NOTEHOLDERS IN THE CONTEXT OF THE CONTEMPLATED INITIAL
PUBLIC OFFERING OF ICADE SANTÉ

On 7 June 2021, Icade SA, the majority shareholder of Icade Santé holding
58.30% of its share capital, announced its intention to have Icade Santé's
shares admitted to trading on the regulated market of Euronext Paris by the end
of 2021 (the "Contemplated IPO"), subject to market conditions, in order to
finance its ambitious development and investment plan.

For the purposes of the Contemplated IPO, Icade Santé will be required, in
accordance with applicable regulations, to change its corporate form from a
société par actions simplifiée to a société anonyme à conseil
d'administration before its shares can be admitted to trading on the regulated
market of Euronext Paris.

In addition, in the context of the Contemplated IPO, it is envisaged to regroup
the international activities of Icade SA's healthcare property investment
activities within Icade Santé, which are currently carried out by Icade
Healthcare Europe, a subsidiary of Icade SA, which will require to extend the
current corporate purpose of Icade Santé (which is currently limited to
France), to international activities.

In this context, the holders of the EUR 500 000 000 notes issued on 4 November
2019 by Icade Santé bearing interest at a rate of 0.875 per cent and maturing
on 4 November 2029 - ISIN : FR0013457967 (the "Notes") were convened in a
general meeting on 27 July 2021 on first convocation and, if the quorum is not
reached, on 2 August 2021 on second convocation, in particular with a view to
approve the change of Icade Santé's corporate form from a société par
actions simplifiée to a société anonyme à conseil d'administration and also
to approve certain modifications of Icade Santé's corporate purpose, including
the extension of its activities (which are currently limited to France) to
international activities. The change of corporate form and the abovementioned
amendments to the by-laws would enter into force from the date of approval by
the French Autorité des marchés financiers of the prospectus relating to the
admission of Icade Santé's shares to trading on the regulated market of
Euronext Paris.

Icade Santé invites the holders of the Notes to consult the section dedicated
to the general meeting of the holders of Notes on the company's website
(www.icade-sante.fr).

Disclaimer

This press release does not contain and does not constitute an offer to sell
securities, or an invitation or the solicitation to invest in securities in
France, in the United States or in any other jurisdiction.

ABOUT ICADE SANTÉ

With a portfolio worth EUR5.2 billion (on a full consolidation basis) as of
December 31, 2020, Icade Santé is the leading investor in private healthcare
facilities in France. A 58.3% owned subsidiary of the Icade Group, Icade Santé
draws on its proven expertise, its long-term shareholders as well as its
extensive knowledge of the real estate value chain. Since 2017, Icade Santé
has pursued a strategy of diversification into the nursing home segment.

Icade and Icade Santé are rated BBB+ with a stable outlook by rating agency
S&P.
The text of this press release is available on the Icade Santé website:
https://icade-sante.fr

CONTACTS

Yoann Nguyen
Head of Investors Relations
+33(0)6 31 58 97 31
yoann.nguyen@icade.fr

Etienne Maurer
Deputy CFO
+33(0)1 41 57 79 02
etienne.maurer@icade.fr

ICADE SANTE's latest news

13/03/2023 20:15

ICADE SANTE (EPA:ICSAA) CONSULTATION OF THE NOTEHOLDERS IN THE CONTEXT OF THE CONTEMPLATED INITIAL PUBLIC OFFERING OF ICADE SANTÉ

Transparency directive : regulatory news

ICADE SANTE's latest news

Other stories